-

My Intelligent Machines Inc. Recognized as a Prominent and Growing Player in the North-American A.I. Sector

MONTREAL, Québec--(BUSINESS WIRE)--My Intelligent Machines Inc. (MIMs) today announced it received the 2020 Red Herring’s Top 100 North America Award, one of the most prestigious prizes granted each year to the 100 most promising private tech companies that are well-positioned to grow at a fast pace.

Red Herring’s editorial team conducted a thorough process for several months among 750+ applicants including MIMs, taking into account many criteria including the disruptive impact our augmented intelligence system is having in the industry, its proof of concept, the Company’s financial performance and market footprint, as well as the quality of our management. Only 138 companies have been selected to present their business endeavour during the final round of the competition.

In the same week, MIMs has also been selected as one of the six c-level startup competitors - and the only Canadian, Quebec-based startup, invited to present during the Grand Finale hosted by FrenchFounders’ Transatlantic Leaders Forum, a French-speaking international business club promoting networking among executives and company founders in the U.S. and around the world.

“Our augmented intelligence system is a complete game changer at the drug discovery level for the entire pharma industry”, said Sarah Jenna, PhD, co-founder and CEO of My Intelligent Machines. “We are delighted that the industry experts, insiders and journalists assembled by Red Herring awarded us this prestigious prize: it’s a clear indication that our business model raises awareness among the industry, including Google, while shedding light on the entire Quebec-based AI ecosystem”, completed Dr. Jenna.

MIMs markets software-as-a-service (SaaS) solutions to pharma and biotech companies. Whereas any conventional AI solution operates as a ‘black box’, MIMs’ software is designed to bring tremendous data processing abilities to the discovery and preclinical stages of any drug development process. It allows for early-stage patients’ stratification and classification with a precision never reached before. MIMs’ technological solution works in synergy with the scientific team, making accurate human biology simulations possible far before incurring significant costs and risks in late-stage clinical development.

Red Herring’s Top 100 North America Awards have become not only a springboard for some of the tech industry’s most prominent names, from Google to Skype, Spotify and Twitter, but also a valued and trusted tool for venture capitalists, experts and analysts predicting trends at the industry’s sharpest edge. Following the current win, MIMs will be invited to present at the Red Herring Top 100 Global event in 2021 and compete with fellow winners from North America, Europe and Asia.

About MIMs

Montreal-based My Intelligent Machines (MIMs) is a leader in artificial intelligence and systems biology. MIMs provides pharmaceutical companies of all sizes with easy-to-implement and interactive augmented intelligence systems, allowing for accurate biological simulations at early drug development stage, to assist scientists in the development of precisely targeted and personalized therapies. For more information, please visit mims.ai

Contacts

To contact Sarah Jenna, Co-founder and CEO, My Intelligent Machines:

Annalie Sabrie Ledesma, Marketing Coordinator
Email: annalie@mims.ai
Phone: 514 462-1519

My Intelligent Machines Inc.

Details
Headquarters: Montreal, QC
Website: www.mims.ai
CEO: Sarah Jenna
Employees: 32
Organization: PRI

Release Summary
MY INTELLIGENT MACHINES INC. RECOGNIZED AS A PROMINENT AND GROWING PLAYER IN THE NORTH-AMERICAN A.I. SECTOR
Release Versions

Contacts

To contact Sarah Jenna, Co-founder and CEO, My Intelligent Machines:

Annalie Sabrie Ledesma, Marketing Coordinator
Email: annalie@mims.ai
Phone: 514 462-1519

Social Media Profiles
More News From My Intelligent Machines Inc.

My Intelligent Machines Launches Powerful New Software for Drug Development in Oncology

MONTREAL--(BUSINESS WIRE)--My Intelligent Machines (MIMs)—a leader in harnessing the power of systems biology, bioinformatics, and artificial intelligence—today launched a product poised to change the way companies prepare for clinical trials in oncology. Using a sophisticated systems biology and machine learning platform built specifically for them, life scientists are now able to predict good responders to new therapies with more than two-times higher performance than other available methodol...

My Intelligent Machines Receives the 2021 AI Innovation Award Granted by ADRIQ

MONTREAL--(BUSINESS WIRE)--My Intelligent Machines (“MIMs”), a leader in artificial intelligence and systems biology, announced it has been granted the 2021 AI Innovation Award by the Association pour le développement de la recherche et l’innovation au Québec (ADRIQ), a Quebec-based research association, during the prestigious Gala that took place virtually on November 25. Key to its selection in the AI category was the Company’s disruptive innovation at the core of its augmented intelligence s...

My Intelligent Machines Receives the Company of the Year 2021 Award Granted by Anges Québec

MONTREAL--(BUSINESS WIRE)--My Intelligent Machines (“MIMs”), a leader in artificial intelligence and systems biology, today announced it has received the Company of the Year 2021 Award by Anges Québec, during their 2021 Annual Gathering which brought together virtually close to 175 participants on June 3rd. MIMs especially stood out thanks to the disruptive innovation at the core of its augmented intelligence software solution, supporting R&D activities applied to life sciences. MIMs’ publi...
Back to Newsroom